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Abstract
Integrin v3 is involved in varied cell biological
activities, including angiogenesis, cell adhesion, and
migration on several extracellular matrix components.
Although v3 is not typically expressed in epithelial
cells, it is expressed in macrophages, activated leuko-
cytes, cytokine-stimulated endothelial cells, osteo-
clasts, and certain invasive tumors. Interestingly, the
adhesion and migration of breast cancer cells on bone
matrix are mediated, in part, by v3. Similar to breast
cancer cells, prostate cancer cells preferentially meta-
stasize to the bone. The biological events that mediate
this metastatic pattern of prostate cancer are not well
defined. This review discusses the role v3 plays in
prostate cancer progression, with specific emphasis on
bone metastasis and on v3 signaling in prostate
cancer cells. The data suggest that v3, in part,
facilitates prostate cancer metastasis to bone by
mediating prostate cancer cell adhesion to and migra-
tion on osteopontin and vitronectin, which are common
proteins in the bone microenvironment. These bio-
logical events require the activation of focal adhesion
kinase and the subsequent activation of PI-3 kinase/Akt
signaling pathway.
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Introduction
Integrins play a significant role in prostate tumor progression
[1]. Schmelz et al. demonstrated that well -differentiated
tumors had a higher expression of 3 and 6 integrins
compared to anaplastic tumors. This study also reported that
an increase in 61 integrin expression on prostate cancer
cells was associated with invasion of the seminal vesicles.
The expression of integrin v3 was not monitored in this
study [1]. Unfortunately, the information regarding the role of
v3 in prostate tumorigenesis and metastasis is limited. This
review will infer from the literature the potential role this
integrin plays in prostate tumor progression.
Integrin v3 mediates cell adhesion and migration on a
variety of extracellular matrix (ECM) proteins, including
vitronectin, fibronectin, fibrinogen, laminin, collagen, osteo-
pontin, and others [2 ]. It is involved in osteoclast adhesion to
bone matrix components osteopontin and bone sialoprotein
(BSP) and subsequent degradation of the bone [3,4]. This
integrin also mediates osteoblast adhesion to osteopontin at
the site of bone resorption [5]. The adhesion of breast cancer
cells to bone matrix and the migration of breast cancer cells in
BSP are mediated by v3 [6,7 ]. Glioblastoma multiforme
adhesion to fibronectinandvitronectin isalsomediatedbyv3
[8 ]. The expression of v3 has been detected on macro-
phages,activated leukocytes,cytokine-stimulatedendothelial
cells, osteoclasts, and certain invasive tumors; however, it is
not commonly expressed in epithelial cells [2 ]. Angiogenesis
facilitates the growth and metastasis of solid tumors by,
providing nutrients to the expanding mass and providing a
pathway for tumor cell dissemination. The expression of v3
on endothelial cells plays an important role in this process [2].
Endothelial cells stimulated by tumor-derived angiogenic
factorsenter the cell cycle andexpress the integrinv3,which
allows endothelial cells to interact with a wide variety of ECM
proteins as they invade the tissue surrounding the tumor.
Antagonists to this integrin induce apoptosis specifically in
angiogenic endothelial cells, thereby facilitating regression in
several tumors including breast [9-11].
One critical function of v3 is to inhibit endothelial cell
apoptosis during angiogenesis. The ligation of endothelial
v3 to osteopontin and vitronectin inhibits apoptosis in
endothelial cell cultures upon serum withdrawal. This v3-
mediated activity requires the activation of NF-B because
nonphosphorylatable IB completely blocks the survival
effect of osteopontin and vitronectin [12]. Nonphosphory-
lated IB binds NF-B in the cytoplasm. When properly
stimulated, IB is phoshorylated, ubiquinated, and
degraded, thereby releasing NF-B to translocate to the
nucleus and activate specific genes. In endothelial cells,
NF-B stimulates the expression of osteoprotegerin, which
has been implicated as a cell survival factor due to its
interaction with TNF-related apoptosis - inducing ligand. The
mechanism used by osteoprotegerin to protect endothelial
cells from apoptosis induced by serum withdrawal is not
known [13].
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The Expression of v3 on Prostate Cancer Cell Lines
The surface expression of v3 is established in commonly
used prostate cancer cell lines, including DU145, PC-3, and
TSU [14,15]. The expression of v3 on LNCaP cells is in
dispute. Although Witkowski et al. [15 ] detected both v and
3 integrin subunits in LNCaP cells, Zheng et al. [16]
demonstrated that LNCaP cells did not express heterodimer
v3. These conflicting results may be due to the types of
antibodies used in each study. The former study [15] used
antibodies to the monomeric v and 3 subunits, whereas the
latter study [16] used antibodies that recognize the v3
heterodimer. In addition to the previously mentioned prostate
cancer cell lines, Putz et al. [17] established four prostate
cancer cell lines that were derived from bone marrow
aspirates and demonstrated that all four cell lines expressed
v and 3 integrin subunits. Interestingly, breast and lung
cancer cell lines that were also derived from bone marrow
aspirates also expressed v3, suggesting that it may play a
role in cancer cell metastasis to the bone marrow.
The Function of v3 in Prostate Cancer Cells
The adhesion of cancer cells to the vascular endothelium is a
critical step in the metastatic cascade and is mediated by
integrins [18,19]. Romanov and Goligorsky [20] used phage
display to identify integrins that are important mediators of
prostate cancer cell adhesion to interleukin-1–stimulated
human umbilical vein endothelial cells (HUVECs). Their data
demonstrated that v3, along with 51 and 31, mediated
PC-3 and DU145 adhesion to HUVEC monolayers. Another
study showed that murine melanoma cell adhesion to micro-
vascular endothelium stimulated by eicosanoid 12(S ) -
hydroxyeicosatetraenoic acid was mediated solely by v3
[21]. However, because Romanov and Goligorsky used
HUVEC, the relevanceof their study toclinical prostate cancer
is questioned because prostate cancer frequently metasta-
sizes to the bone. In addition, prostate cancer cell lines have
been shown to adhere preferentially to human bone marrow
endothelial cells over HUVEC [22]. While v3 may be
important for prostate cancer cell adhesion to HUVEC, the
role this integrin plays in prostate cancer cell adhesion to bone
marrow endothelium has not been determined.
Prostate cancer cell adhesion to and migration on
components present in the bone matrix are mediated, in
part, by v3 [23]. A well -characterized antibody to v3
(LM609) reduced DU145 cell adhesion to crude bone protein
extract by 94%. The protein makeup of the crude bone
protein extract was not determined; however, osteopontin
and vitronectin are common proteins in mature bone and
appropriate ligands for v3 [16,24]. Zheng et al. [16]
demonstrated that PC-3 cell adhesion and migration to
vitronectin and osteopontin were v3-dependent. LNCaP
cells did not express this integrin and therefore did not
adhere to nor migrate on vitronectin and osteopontin.
Exogenous expression of v3 in LNCaP cells mediated
adhesion to vitronectin but not to osteopontin. Surprisingly,
the LNCaP cells used in a study performed by Witkowski et
al. [15] expressed v3, yet these cells did not adhere to
vitronectin, suggesting that the monomeric forms of this
integrin were not functionally active. LNCaP cell adhesion to
osteopontin was not evaluated in that study.
Osteopontin- induced growth of prostate cancer cells in
the bone marrow is mediated by v3 [25,26]. One study
demonstrated that osteopontin stimulated anchorage- inde-
pendent growth of cell lines LNCaP and C4-2, an androgen-
independent subline of LNCaP. Interestingly, osteopontin
was detected in greater amounts in androgen- independent
prostate cancer cell lines such PC-3 and C4-2, suggesting
that it contributes to androgen- independent growth in the
bone [25]. Lecrone et al. [26] confirmed this observation by
showing that bone-derived osteopontin triggered calcium
[Ca2+ ] -dependent signalling in PC-3 cells. An antibody to
v3 inhibited these Ca
2+ signals in PC-3 cells. Fluctuations
in intracellular Ca2+ regulate signal transduction events that
are often associated with cell growth. The fluctuations were
not observed in DU145 and LNCaP in the presence of any
bone-derived fractions. Interestingly, DU145 cells express
v and 3 integrin monomers, but the heterodimer expres-
sion of v3 is not known. Moreover, secretory products from
PC-3 cells but not LNCaP cells upregulated osteopontin
expression in MC3T3-E1 cells, an osteoblastic cell line [27].
These observations suggest that prostate cancer cells
entering the bone environment are surrounded by osteo-
pontin from a few sources, including the bone matrix,
osteoblasts, and the cancer cells themselves. The presence
of osteopontin can mediate preferential adhesion, migration,
and growth of prostate cancer cells expressing v3.
Another investigation demonstrated that v3 was
involved in bombesin stimulation of prostate cancer cell
motility [28]. Neuroendocrine cells in prostate cancer
express and secrete bombesin- like peptides, suggesting
that these peptides are involved in prostate cancer pro-
gression. The study demonstrated that bombesin increased
PC-3 cell invasion through matrigel, but did not alter its
adhesion to ECM proteins including vitronectin. Bombesin
also increased the tyrosine phosphorylation of a 95-kDa
protein, which was coimmunoprecipitated with the v, 3, and
5 integrin subunits. In addition, bombesin treatment caused
1, 3, and 5 integrin subunits to coimmunoprecipitate with
focal adhesion kinase (FAK). This suggests that the bomb-
esin signaling is mediated by v3 and FAK activation.
The functions of v3 in prostate cancer cells are
mediated by FAK, which activates the phosphatidylinositol
3-kinase (PI -3 kinase) /Akt pathway [16,24] (Figure 1 ).
Transfection of FAK-related nonkinase, which competes
with FAK for its correct localization and phosphorylation, in
LNCaP cells previously transfected with v3 inhibited the
migration of these cells on vitronectin. FAK was also
activated in PC-3 cells adherent to vitronectin and v3-
transfected LNCaP adherent to osteopontin [16,24].
Although FAK phosphorylation was not evaluated in PC-3
cells adherent to osteopontin, one can speculate that FAK
was phosphorylated because the PI-3 kinase/Akt pathway
was activated in these cells as well [16].
The role of the PI-3 kinase/Akt pathway in prostate
cancer cell adhesion and migration on both osteoponitin and
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vitronectin has been demonstrated by using wortmanin, a
specific PI -3 kinase inhibitor. This compound inhibited PC-3
cell adhesion to and migration on both substrates [16]. The
PI-3 kinase/Akt pathway may also be involved in androgen-
independent growth of prostate cancer cells described
earlier [25]. Once activated by an upstream kinase such
as FAK, this pathway facilitates cell survival and proliferation
by increasing cell cycle regulator E2F, which mediates
progression through the cell cycle, and by preventing the
proapoptotic activity of BAD. The phosphorylation of BAD by
Akt-associated protein kinase B (PKB) prevents it from
heterodimerizing with Bcl -2 or Bcl -XL. These well -known
antiapoptotic proteins may be able to provide survival signals
that protect prostate cancer cells from apoptosis induced by
various stresses like hormone ablation and chemotherapy
[29,30]. FAK also activates NF-B, which is known to
regulate the transcription of antiapoptotic proteins [30].
Summary
Cell adhesion molecules (CAMs) are important for the
preferential metastasis of prostate cancer to bone
[19,22,31]. These CAMs mediate the initial adhesion to
the human bone marrow endothelium [22,31] and then the
underlying bone matrix [19]. Studies have shown that v3
mediates prostate cancer cell adhesion to and migration on
vitronectin and osteopontin, which are components of the
bone microenvironment [16]. This integrin also mediates
osteopontin-associated androgen- independent growth of
prostate cancer cells, a common characteristic of advanced
prostate cancer [25]. Ligation of v3 with its respective
ligands activates FAK and subsequently the PI-3 kinase/
Akt pathway, resulting in a variety of biological effects,
including suppression of apoptosis [29]. Although it is not
known if direct engagement of v3 in prostate cells
prevents apoptosis through the PI-3 kinase/Akt pathway
[16], the data presented suggest that v3 through this
signal pathway may be involved in prostate cancer meta-
stasis to bone.
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Figure 1. v3 signaling pathway in prostate cancer cells. Ligation of v3 with multiple ligands ( i.e., osteopontin, BSP, or vitronectin ) activates FAK, which interacts
and activates PI -3 kinase [ 23 ]. The products of PI - 3 kinase activity recruit PKB /Akt to the cell membrane where it is activated by phosphorylation and it
phosphorylates several substrates to elicit a variety of biological responses, including cell survival, adhesion, and migration. Although NF -B is potentially involved
in the v3 signal transduction pathway [8 ], its role in this signaling pathway is not known for prostate cancer cells.
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